☰

Robert Martuza, MD - Publications

Affiliations: 
1993-2000 Neurosurgery Georgetown University, Washington, DC 
 2000-2017 Neurosurgery Massachusetts General Hospital, Boston, MA 
Tree Info Grants Similar researchers PubMed Report error

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Shimizu K, Kahramanian A, Jabbar MADA, Turna Demir F, Gokyer D, Uthamacumaran A, Rajan A, Saad MA, Gorham J, Wakimoto H, Martuza RL, Rabkin SD, Hasan T, Wakimoto H. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies. Cancer Letters. 572: 216363. PMID 37619813 DOI: 10.1016/j.canlet.2023.216363  0.307
2021 Jahan N, Ghouse SM, Martuza RL, Rabkin SD. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses. 13. PMID 34578321 DOI: 10.3390/v13091740  0.301
2020 Li M, Li G, Kiyokawa J, Tirmizi Z, Richardson LG, Ning J, Das S, Martuza RL, Stemmer-Rachamimov A, Rabkin SD, Wakimoto H. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications. 8: 221. PMID 33308315 DOI: 10.1186/s40478-020-01096-0  0.325
2019 Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD, Martuza RL. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Molecular Therapy Oncolytics. 13: 58-66. PMID 31016228 DOI: 10.1016/j.omto.2019.03.008  0.306
2018 Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD. RESTRICTION OF γ34.5-DELETED ONCOLYTIC HERPES SIMPLEX VIRUS REPLICATION IN GLIOBLASTOMA STEM-LIKE CELLS. Journal of Virology. PMID 29793956 DOI: 10.1128/JVI.00246-18  0.306
2016 Saha D, Martuza R, Rabkin S. Abstract B116: Immunovirotherapy in combination with immune checkpoint inhibitors for treating glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B116  0.39
2015 Ning J, Wakimoto H, Martuza R, Rabkin S. Abstract 4227: PARP inhibitors sensitize glioblastoma stem cells to oncolytic herpes simplex virus therapy Cancer Research. 75: 4227-4227. DOI: 10.1158/1538-7445.Am2015-4227  0.348
2015 Venteicher A, Tirosh I, Hebert C, Escalante L, Nahed B, Cahill D, Curry W, Martuza R, Bernstein B, Louis D, Regev A, Suva M. STEM-22LARGE-SCALE SINGLE-CELL RNA-seq REVEALS A DEVELOPMENTAL CELLULAR HIERARCHY IN HUMAN OLIGODENDROGLIOMA Neuro-Oncology. 17: v212.4-v213. DOI: 10.1093/Neuonc/Nov234.22  0.402
2015 Nigim F, Rabkin SD, Brastianos P, Ramesh V, Cahill D, Santagata S, Martuza RL, Wakimoto H. MNGO-16ESTABLISHMENT OF A PATIENT - DERIVED ORTHOTOPIC MALIGNANT MENINGIOMA MODEL FOR THE DEVELOPMENT OF TARGETED THERAPY Neuro-Oncology. 17: v133.2-v133. DOI: 10.1093/Neuonc/Nov220.15  0.337
2014 Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro-Oncology. 16: 1057-66. PMID 24470552 DOI: 10.1093/Neuonc/Not317  0.304
2013 Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proceedings of the National Academy of Sciences of the United States of America. 110: 12006-11. PMID 23754388 DOI: 10.1073/pnas.1307935110  0.342
2013 Las Heras F, Martuza R, Caruso P, Rincon S, Stemmer-Rachamimov A. 24-Year-old woman with an internal auditory canal mass Brain Pathology. 23: 361-362. PMID 23587143 DOI: 10.1111/Bpa.12055  0.357
2012 Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SD. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro-Oncology. 14: 132-44. PMID 22067563 DOI: 10.1093/Neuonc/Nor195  0.311
2011 Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G. Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4484-93. PMID 21558403 DOI: 10.1158/1078-0432.Ccr-11-0575  0.31
2011 Zhang W, Fulci G, Rabkin SD, Zhang X, Martuza RL. Abstract 2568: Combination treatment of bevacizumab and oncolytic HSV armed with angiostatin show enhanced antitumoral and antiangiogenic effects Cancer Research. 71: 2568-2568. DOI: 10.1158/1538-7445.Am2011-2568  0.311
2009 Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research. 69: 3472-81. PMID 19351838 DOI: 10.1158/0008-5472.Can-08-3886  0.324
2009 Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 51-6. PMID 18957963 DOI: 10.1038/Mt.2008.232  0.323
2009 Kanai R, Wakimoto H, Martuza RL, Rabkin SD. Abstract C176: Combining oncolytic herpes simplex virus and chemotherapy: G47 and temozolomide synergize in killing glioma stem cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C176  0.31
2008 Farrell CJ, Zaupa C, Barnard Z, Maley J, Martuza RL, Rabkin SD, Curry WT. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7711-6. PMID 19047097 DOI: 10.1158/1078-0432.CCR-08-1364  0.329
2007 Jeyaretna DS, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurgical Focus. 22: E4. PMID 17613221 DOI: 10.3171/Foc.2007.22.6.5  0.32
2007 Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Therapy. 14: 460-7. PMID 17304235 DOI: 10.1038/Sj.Cgt.7701037  0.447
2006 Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6791-9. PMID 17121900 DOI: 10.1158/1078-0432.CCR-06-0263  0.335
2006 Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 789-97. PMID 17045531 DOI: 10.1016/j.ymthe.2006.07.011  0.346
2006 Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Therapy. 17: 20-30. PMID 16409122 DOI: 10.1089/Hum.2006.17.20  0.41
2006 Messerli S, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Erratum: Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2 (Human Gene Therapy (January 2006) 17, 1 (20-30)) Human Gene Therapy. 17. DOI: 10.1089/Hum.2006.17.796  0.323
2006 Prabhakar S, Messerli S, Rabkin S, Martuza R, Breakefield XO. 151. Treatment of Experimental Schwannomas with HSV Recombinant and Amplicon Vectors Molecular Therapy. 13: S59. DOI: 10.1016/J.Ymthe.2006.08.174  0.411
2005 Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7886-90. PMID 16278413 DOI: 10.1158/1078-0432.CCR-05-1090  0.308
2001 Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (New York, N.Y.). 3: 451-6. PMID 11687957 DOI: 10.1038/Sj.Neo.7900193  0.326
2001 Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Therapy. 8: 332-9. PMID 11313808 DOI: 10.1038/Sj.Gt.3301392  0.364
2001 Barker FG, McKenna M, Poe D, Nadol J, Chapman P, Martuza R, Ojemann RG. 790 Pediatric Acoustic Neuromas: NF2 and Sporadic Tumors Neurosurgery. 49: 533-533. DOI: 10.1097/00006123-200108000-00154  0.37
2000 Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 324-9. PMID 11020347 DOI: 10.1006/mthe.2000.0130  0.305
2000 Martuza RL. Conditionally replicating herpes vectors for cancer therapy. The Journal of Clinical Investigation. 105: 841-6. PMID 10749560 DOI: 10.1172/JCI9744  0.336
1999 Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice Gene Therapy. 6: 1751-1758. PMID 10516725 DOI: 10.1038/sj.gt.3301003  0.315
1999 Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Therapy. 6: 564-72. PMID 10476216 DOI: 10.1038/sj.gt.3300861  0.335
1999 Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Human Gene Therapy. 10: 385-93. PMID 10048391 DOI: 10.1089/10430349950018832  0.329
1995 Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. Journal of Neuro-Oncology. 23: 23-9. PMID 7542695 DOI: 10.1007/Bf01058456  0.302
1992 Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research. 33: 493-503. PMID 1335091 DOI: 10.1002/jnr.490330316  0.31
1991 Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R. TP53 gene mutations and 17p deletions in human astrocytomas. Genes, Chromosomes & Cancer. 3: 323-31. PMID 1686725 DOI: 10.1002/Gcc.2870030502  0.366
1988 Martuza RL, Seizinger BR, Jacoby LB, Rouleau GA, Gusella JF. The molecular biology of human glial tumors. Trends in Neurosciences. 11: 22-7. PMID 2469150 DOI: 10.1016/0166-2236(88)90045-8  0.316
1987 Seizinger BR, Rouleau G, Ozelius LJ, Lane AH, St George-Hyslop P, Huson S, Gusella JF, Martuza RL. Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science (New York, N.Y.). 236: 317-9. PMID 3105060 DOI: 10.1126/Science.3105060  0.327
1986 Cohen AM, Wood WC, Bamberg M, Martuza R. Cytotoxicity of human brain tumors by hematoporphyrin derivative. The Journal of Surgical Research. 41: 81-3. PMID 3747501 DOI: 10.1016/0022-4804(86)90012-0  0.354
1983 Martuza RL. Genetics in neuro-oncology. Clinical Neurosurgery. 31: 417-40. PMID 6437720 DOI: 10.1093/Neurosurgery/31.Cn_Suppl_1.417  0.315
Show low-probability matches.